News coverage about Sinovac Biotech (NASDAQ:SVA) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sinovac Biotech earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.0744433308972 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, BidaskClub cut shares of Sinovac Biotech from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th.
Sinovac Biotech (SVA) opened at $7.78 on Tuesday. Sinovac Biotech has a 52-week low of $4.60 and a 52-week high of $7.84.
WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/21/sernova-corp-sva-receiving-somewhat-positive-news-coverage-study-shows.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.